Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;21(3):173-80.

Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children

Affiliations

Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children

George Rust et al. Am J Manag Care. 2015 Mar.

Abstract

Background: Many asthma-related exacerbations could be prevented by consistent use of daily inhaled corticosteroid therapy (ICS-Rx).

Objectives: We sought to measure the potential cost savings that could accrue from increasing ICS-Rx adherence in children.

Study design: We measured observed costs for a cohort of 43,156 Medicaid-enrolled children in 14 southern states whose initial ICS-Rx was prescribed in 2007.

Methods: Adherence rates and associated costs were calculated from Medicaid claims. Children were categorized as high or low adherence based on the ratio of ICS-Rx claims filled to total asthma drug claims. Branching tree simulation was used to project the potential cost savings achieved by increasing the proportion of children with ICS-Rx to total asthma Rx ratios greater than 0.5 to 20%, 40%, 60%, 80%, and 100%.

Results: Increasing the proportion of children who maintain higher adherence after initial ICS-Rx to 40% would generate savings of $95 per child per year. An intervention costing $10 per member per month that resulted in even half of the children maintaining high adherence would generate a 98% return on investment for managed care plans or state Medicaid programs. Net costs decreased incrementally at each level of increase in ICS-Rx adherence. The projected Medicaid cost savings for these 14 states in 2007 ranged from $8.2 million if 40% of the children achieved high adherence, to $57.5 million if 80% achieved high adherence.

Conclusions: If effective large-scale interventions can be found, there are substantial cost savings to be gained from even modest increases in real-world adherence to ICS-Rx among Medicaid-enrolled children with asthma.

PubMed Disclaimer

Conflict of interest statement

Author Disclosures: Dr Zhang reports no conflicts of interest.

Figures

Figure
Figure. Model Structure of Decision Tree Analysis
ED indicates emergency department; ICS-Rx, inhaled corticosteroid. Initial model uses outcomes for observed high adherence rate of 33.3% to establish baseline costs; model then is rerun at simulated proportions of children in high-adherence group of 40%, 60%, 80%, and 100% to assess potential reductions in costs.

Similar articles

Cited by

References

    1. Data, statistics, and surveillance: asthma surveillance data. [Accessed May 7, 2014];CDC website. http://www.cdc.gov/asthma/asthmadata.htm.
    1. Barbara Bloom, Jones Lindsay I, Gulnar Freeman. [Accessed May 7, 2014];Division of Health Interview Statistics, CDC. Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012:4. CDC website. www.cdc.gov/nchs/data/series/sr_10/sr10_258.pdf. Published December 2013.
    1. National Hospital Ambulatory Medical Care Survey: 2010 emergency department summary tables. Table 13: twenty leading primary diagnosis groups for emergency department visits, by patient age and sex, United States, 2010. [Accessed May 7, 2014];CDC website. http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2010_ed_web_tables.pdf.
    1. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008;8(4):CD003135. - PubMed
    1. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF The Dutch Chronic Non-specific Lung Disease Study Group. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis. 1992;146(3):547–554. - PubMed

Publication types

Substances